title: Effect of recombinant human follicle-stimulating hormone and luteinizing hormone on in vitro maturation of porcine oocytes evaluated by the subsequent in vitro development of embryos obtained by in vitro fertilization, intracytoplasmic sperm injection, or parthenogenetic activation.
abstract: The aim of this work was to study the effect of recombinant human (rh) FSH and LH on in vitro maturation of pig oocytes compared with a conventional hormonal supplement based on equine (PMSG) and human chorionic gonadotropins (hCG), as evaluated by the developmental ability of 3 types of pig embryos obtained by in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), or artificial activation (ATA). In Exp. 1, one cumulus-oocyte complex group (A group) was supplemented with rh-FSH and rh-LH (0.1 IU/mL each), and the other group (B group) was supplemented with PMSG and hCG (10 IU/mL each). No differences in nuclear maturation between the A and B groups were observed (68.5 vs. 71.4%, respectively). No differences were detected between hormonal treatments in the rates of cleavage or blastocyst formation of ATA, IVF, and ICSI embryos. Total cell number of the embryos was not significantly different in any experimental group (A: 31.1, 28.5, and 19.8 vs. B: 25.2, 25.5, and 20.6 for ATA, IVF, and ICSI embryos, respectively). In Exp. 2, the effects of different concentrations of rh-FSH and rh-LH (0.5, 0.1, or 0.05 IU/mL) in maturation medium on nuclear maturation and in vitro development of embryos obtained by IVF were studied. No effect of different hormonal concentrations on blastocyst formation rates was observed (8.5, 13.0, and 5.7%, respectively). Blastocyst cell number was not different in any experimental group. In conclusion, the results obtained here permit us to substitute PMSG and hCG with rh-FSH and rh-LH and to produce pig embryos obtained by IVF, ICSI, or ATA.
authors.affiliation: Centro de Investigación y Tecnología Animal, Instituto Valenciano de Investigaciones Agrarias, Segorbe, 12400 Castellón, Spain. masilver@ivia.es
authors.forename: M A
authors.initials: MA
authors.lastname: Silvestre
authors.forename: J
authors.initials: J
authors.lastname: Alfonso
authors.forename: E
authors.initials: E
authors.lastname: García-Mengual
authors.forename: I
authors.initials: I
authors.lastname: Salvador
authors.forename: C C
authors.initials: CC
authors.lastname: Duque
authors.forename: I
authors.initials: I
authors.lastname: Molina
mesh_terms: D000818:Animals; D005299:Fertility Agents / Q000494:pharmacology; D005307:Fertilization in Vitro / Q000379:methods / Q000662:veterinary*; D005640:Follicle Stimulating Hormone / Q000494:pharmacology*; D006801:Humans; D007986:Luteinizing Hormone / Q000494:pharmacology*; D008297:Male; D009865:Oocytes / Q000187:drug effects* / Q000254:growth & development*; D010312:Parthenogenesis / Q000187:drug effects / Q000502:physiology*; D011994:Recombinant Proteins / Q000494:pharmacology; D013094:Spermatozoa; D013552:Swine / Q000196:embryology*
chemical_list: D005299:Fertility Agents; D011994:Recombinant Proteins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone